GlassScriptPhysician profile
Mary Clemons
NPI 1326281874
$3,248.80
in general payments reported to CMS, 2019-2025
29 companies · $890 in 2025
The $890 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $154 · 2021: $330 · 2022: $451 · 2023: $631 · 2024: $644 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076 · Entertainment: $89.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.38 |
| Entertainment | $89.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $349.32 | 2019-2023 | |
| Abbvie INC. | $322.14 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Mallinckrodt Hospital Products INC. | $240.76 | 2022-2025 | Acthar |
| Amgen INC. | $236.55 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $232.79 | 2021-2023 | Tepezza |
| Oyster Point Pharma, INC. | $216.69 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $208.41 | 2020-2024 | Cequa |
| Biotissue Holdings INC. | $197.66 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $190.47 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Harrow Eye, LLC | $118.41 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $117.48 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.29 | 2019-2021 | |
| Alcon Vision LLC | $98.46 | 2019-2022 | |
| Optos, INC. | $89.45 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Aerie Pharmaceuticals, INC. | $67.13 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $61.58 | 2019-2025 | Oxervate |
| Thea Pharma INC. | $57.37 | 2022-2025 | Iyuzeh |
| Boston Scientific Corporation | $45.57 | 2023-2024 | Versacross Access Solution, Rhythmia Mapping System |
| Ocular Therapeutix, INC. | $44.65 | 2024-2025 | Dextenza |
| Allergan, INC. | $43.50 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $39.41 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $29.55 | 2023 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $26.91 | 2024 | Xdemvy |
| Shire North American Group INC | $23.41 | 2019 | |
| Rxsight INC | $21.79 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Axogen | $18.36 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.88 | 2021 | |
| Coopervision INC. | $14.49 | 2022 | |
| Mallinckrodt Enterprises LLC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Clemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.